{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:48:02Z","timestamp":1785174482253,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,22]]},"DOI":"10.7759\/cureus.69919","type":"journal-article","created":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T15:31:17Z","timestamp":1727019077000},"source":"Crossref","is-referenced-by-count":9,"title":["Resmetirom: A Systematic Review of the Revolutionizing Approach to Non-alcoholic Steatohepatitis Treatment Focusing on Efficacy, Safety, Cost-Effectiveness, and Impact on Quality of Life"],"prefix":"10.7759","author":[{"given":"Parikshit","family":"Bittla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Pavitra","family":"Paidimarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriya","family":"Ayuthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashkumar D","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moyal Z","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna  A","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani N","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012, 142:1592-609. 10.1053\/j.gastro.2012.04.001","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels S","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y, et al.. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022, 22:63. 10.1186\/s12902-022-00980-1","journal-title":"BMC Endocr Disord"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2007.02.011","article-title":"Pathogenesis of non-alcoholic steatohepatitis: human data","volume":"11","author":"Edmison J","year":"2007","unstructured":"Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis. 2007, 11:75-104, ix. 10.1016\/j.cld.2007.02.011","journal-title":"Clin Liver Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90235-6","article-title":"Nonalcoholic steatohepatitis: an expanded clinical entity","volume":"107","author":"Bacon BR","year":"1994","unstructured":"Bacon BR, Farahvash MJ, Janney CG, et al.. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994, 107:1103-9. 10.1016\/0016-5085(94)90235-6","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad P","year":"2003","unstructured":"Mofrad P, Contos MJ, Haque M, et al.. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003, 37:1286-92. 10.1053\/jhep.2003.50229","journal-title":"Hepatology"},{"key":"ref7","article-title":"Nonalcoholic steatohepatitis and the \"bright liver syndrome\": should a recently expanded clinical entity be further expanded?","volume":"90","author":"Lonardo A","year":"1995","unstructured":"Lonardo A, Bellini M, Tondelli E, Frazzoni M, Grisendi A, Pulvirenti M, Della Casa G. Nonalcoholic steatohepatitis and the \"bright liver syndrome\": should a recently expanded clinical entity be further expanded?. Am J Gastroenterol. 1995, 90:2072-4.","journal-title":"Am J Gastroenterol"},{"key":"ref8","article-title":"Role of diet and lifestyle changes in nonalcoholic fatty liver disease","volume":"20","author":"Nseir W","year":"2014","unstructured":"Nseir W, Hellou E, Assy N. Role of diet and lifestyle changes in nonalcoholic fatty liver disease. World J Gastroenterol. 2014, 20:9338-44.","journal-title":"World J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez M","year":"2017","unstructured":"Romero-G\u00f3mez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017, 67:829-46. 10.1016\/j.jhep.2017.05.016","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/nxz147","article-title":"Mediterranean diet rich in extra-virgin olive oil is associated with a reduced prevalence of nonalcoholic fatty liver disease in older individuals at high cardiovascular risk","volume":"149","author":"Pint\u00f3 X","year":"2019","unstructured":"Pint\u00f3 X, Fanlo-Maresma M, Corbella E, et al.. Mediterranean diet rich in extra-virgin olive oil is associated with a reduced prevalence of nonalcoholic fatty liver disease in older individuals at high cardiovascular risk. J Nutr. 2019, 149:1920-9. 10.1093\/jn\/nxz147","journal-title":"J Nutr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(97)80287-5","article-title":"Therapeutic effects of restricted diet and exercise in obese patients with fatty liver","volume":"27","author":"Ueno T","year":"1997","unstructured":"Ueno T, Sugawara H, Sujaku K, et al.. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997, 27:103-7. 10.1016\/s0168-8278(97)80287-5","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"Takahashi H","year":"2022","unstructured":"Takahashi H, Kessoku T, Kawanaka M, et al.. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun. 2022, 6:120-32. 10.1002\/hep4.1696","journal-title":"Hepatol Commun"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01663-y","article-title":"A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)","volume":"11","author":"Ghosal S","year":"2021","unstructured":"Ghosal S, Datta D, Sinha B. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Sci Rep. 2021, 11:22063. 10.1038\/s41598-021-01663-y","journal-title":"Sci Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066254","article-title":"Effects of bariatric surgery on mortality in Swedish obese subjects","volume":"357","author":"Sj\u00f6str\u00f6m L","year":"2007","unstructured":"Sj\u00f6str\u00f6m L, Narbro K, Sj\u00f6str\u00f6m CD, et al.. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007, 357:741-52. 10.1056\/NEJMoa066254","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison SA","year":"2021","unstructured":"Harrison SA, Bashir M, Moussa SE, McCarty K, Pablo Frias J, Taub R, Alkhouri N. Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH. Hepatol Commun. 2021, 5:573-88. 10.1002\/hep4.1657","journal-title":"Hepatol Commun"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison SA","year":"2023","unstructured":"Harrison SA, Taub R, Neff GW, et al.. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023, 29:2919-28. 10.1038\/s41591-023-02603-1","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.07.039","article-title":"Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life","volume":"20","author":"Younossi ZM","year":"2022","unstructured":"Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life. Clin Gastroenterol Hepatol. 2022, 20:1354-1361.e7. 10.1016\/j.cgh.2021.07.039","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-022-00370-2","article-title":"Early cost-effectiveness and price threshold analyses of resmetirom: an investigational treatment for management of nonalcoholic steatohepatitis","volume":"7","author":"Javanbakht M","year":"2023","unstructured":"Javanbakht M, Fishman J, Moloney E, Rydqvist P, Ansaripour A. Early cost-effectiveness and price threshold analyses of resmetirom: an investigational treatment for management of nonalcoholic steatohepatitis. Pharmacoecon Open. 2023, 7:93-110. 10.1007\/s41669-022-00370-2","journal-title":"Pharmacoecon Open"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: an orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"19","author":"Karim G","year":"2023","unstructured":"Karim G, Bansal MB. Resmetirom: an orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. touchREV Endocrinol. 2023, 19:60-70. 10.17925\/EE.2023.19.1.60","journal-title":"touchREV Endocrinol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031102","article-title":"Development of thyroid hormones and synthetic thyromimetics in non-alcoholic fatty liver disease","volume":"23","author":"Zhao M","year":"2022","unstructured":"Zhao M, Xie H, Shan H, Zheng Z, Li G, Li M, Hong L. Development of thyroid hormones and synthetic thyromimetics in non-alcoholic fatty liver disease. Int J Mol Sci. 2022, 23:10.3390\/ijms23031102","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1210\/en.2014-1302","article-title":"Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism","volume":"155","author":"Bohinc BN","year":"2014","unstructured":"Bohinc BN, Michelotti G, Xie G, et al.. Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism. Endocrinology. 2014, 155:4591-601. 10.1210\/en.2014-1302","journal-title":"Endocrinology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-14-2-184","article-title":"Thyroid hormone receptors: multiple forms, multiple possibilities","volume":"14","author":"Lazar MA","year":"1993","unstructured":"Lazar MA. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev. 1993, 14:184-93. 10.1210\/edrv-14-2-184","journal-title":"Endocr Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1750553","article-title":"Insight into the physiological actions of thyroid hormone receptors from genetically modified mice","volume":"175","author":"O'Shea PJ","year":"2002","unstructured":"O'Shea PJ, Williams GR. Insight into the physiological actions of thyroid hormone receptors from genetically modified mice. J Endocrinol. 2002, 175:553-70. 10.1677\/joe.0.1750553","journal-title":"J Endocrinol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.22.8329-8342.2000","article-title":"Cloning and characterization of two novel thyroid hormone receptor beta isoforms","volume":"20","author":"Williams GR","year":"2000","unstructured":"Williams GR. Cloning and characterization of two novel thyroid hormone receptor beta isoforms. Mol Cell Biol. 2000, 20:8329-42. 10.1128\/MCB.20.22.8329-8342.2000","journal-title":"Mol Cell Biol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60580","article-title":"Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy","volume":"122","author":"Sinha RA","year":"2012","unstructured":"Sinha RA, You SH, Zhou J, et al.. Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. J Clin Invest. 2012, 122:2428-38. 10.1172\/JCI60580","journal-title":"J Clin Invest"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.03.023","article-title":"3,5-diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet","volume":"51","author":"Mollica MP","year":"2009","unstructured":"Mollica MP, Lionetti L, Moreno M, et al.. 3,5-diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet. J Hepatol. 2009, 51:363-70. 10.1016\/j.jhep.2009.03.023","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1210\/en.2010-0491","article-title":"Tissue distribution and cardiac metabolism of 3-iodothyronamine","volume":"151","author":"Saba A","year":"2010","unstructured":"Saba A, Chiellini G, Frascarelli S, et al.. Tissue distribution and cardiac metabolism of 3-iodothyronamine. Endocrinology. 2010, 151:5063-73. 10.1210\/en.2010-0491","journal-title":"Endocrinology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106923","article-title":"Modulation of gene expression by 3-iodothyronamine: genetic evidence for a lipolytic pattern","volume":"9","author":"Mariotti V","year":"2014","unstructured":"Mariotti V, Melissari E, Iofrida C, et al.. Modulation of gene expression by 3-iodothyronamine: genetic evidence for a lipolytic pattern. PLoS One. 2014, 9:e106923. 10.1371\/journal.pone.0106923","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-5521(98)90168-5","article-title":"A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor","volume":"5","author":"Chiellinil G","year":"1998","unstructured":"Chiellinil G, Aprilettl JW, Yoshiharal HA, et al.. A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol. 1998, 5:299-306. 10.1016\/S1074-5521(98)90168-5","journal-title":"Chem Biol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1708899","article-title":"Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)","volume":"29","author":"Alkhouri N","year":"2020","unstructured":"Alkhouri N. Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196). Expert Opin Investig Drugs. 2020, 29:99-101. 10.1080\/13543784.2020.1708899","journal-title":"Expert Opin Investig Drugs"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1210\/endo.141.9.7681","article-title":"The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity","volume":"141","author":"Trost SU","year":"2000","unstructured":"Trost SU, Swanson E, Gloss B, et al.. The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology. 2000, 141:3057-64. 10.1210\/endo.141.9.7681","journal-title":"Endocrinology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1677\/JOE-08-0539","article-title":"A TRbeta-selective agonist confers resistance to diet-induced obesity","volume":"203","author":"Amorim BS","year":"2009","unstructured":"Amorim BS, Ueta CB, Freitas BC, et al.. A TRbeta-selective agonist confers resistance to diet-induced obesity. J Endocrinol. 2009, 203:291-9. 10.1677\/JOE-08-0539","journal-title":"J Endocrinol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1210\/en.2010-0813","article-title":"In vivo activity of the thyroid hormone receptor beta- and \u03b1-selective agonists GC-24 and CO23 on rat liver, heart, and brain","volume":"152","author":"Grijota-Mart\u00ednez C","year":"2011","unstructured":"Grijota-Mart\u00ednez C, Samarut E, Scanlan TS, Morte B, Bernal J. In vivo activity of the thyroid hormone receptor beta- and \u03b1-selective agonists GC-24 and CO23 on rat liver, heart, and brain. Endocrinology. 2011, 152:1136-42. 10.1210\/en.2010-0813","journal-title":"Endocrinology"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905633","article-title":"Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia","volume":"362","author":"Ladenson PW","year":"2010","unstructured":"Ladenson PW, Kristensen JD, Ridgway EC, et al.. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010, 362:906-16. 10.1056\/NEJMoa0905633","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00573.2012","article-title":"Thyroid hormone receptor-\u03b2 agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways","volume":"305","author":"Vatner DF","year":"2013","unstructured":"Vatner DF, Weismann D, Beddow SA, et al.. Thyroid hormone receptor-\u03b2 agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways. Am J Physiol Endocrinol Metab. 2013, 305:E89-100. 10.1152\/ajpendo.00573.2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison SA","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, et al.. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024, 390:497-509. 10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03426.x","article-title":"Health-related quality of life in patients with non-alcoholic fatty liver disease","volume":"26","author":"Dan AA","year":"2007","unstructured":"Dan AA, Kallman JB, Wheeler A, et al.. Health-related quality of life in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2007, 26:815-20. 10.1111\/j.1365-2036.2007.03426.x","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/283423-resmetirom-a-systematic-review-of-the-revolutionizing-approach-to-non-alcoholic-steatohepatitis-treatment-focusing-on-efficacy-safety-cost-effectiveness-and-impact-on-quality-of-life","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T15:31:20Z","timestamp":1727019080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/283423-resmetirom-a-systematic-review-of-the-revolutionizing-approach-to-non-alcoholic-steatohepatitis-treatment-focusing-on-efficacy-safety-cost-effectiveness-and-impact-on-quality-of-life"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,22]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.69919","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,22]]}}}